Related Experiment Video

Updated: Dec 26, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.3K

[Experience of Treatment with Lenvatinib in Patients with Advanced HCC-A in a Single Institution]

Yoshiteru Katsura1, Yutaka Takeda, Yoshiaki Ohmura

  • 1Dept. of Surgery, Kansai Rosai Hospital.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 12, 2020
PubMed

Insights

Lenvatinib showed promising efficacy in advanced hepatocellular carcinoma (HCC) patients, achieving high response and survival rates with manageable toxicity. This study supports lenvatinib as a standard treatment option for advanced HCC.

Area of Science:

  • Hepatobiliary Cancers
  • Oncology
  • Pharmacology

Background:

  • Advanced hepatocellular carcinoma (HCC) presents a significant clinical challenge.
  • Effective systemic therapies are crucial for improving outcomes in HCC patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of lenvatinib in patients with advanced HCC.
  • To determine key efficacy endpoints including response rates and survival in this patient cohort.

Main Methods:

  • A cohort of 7 patients with advanced HCC received lenvatinib treatment.
  • Data collected included patient demographics, Eastern Cooperative Oncology Group (ECOG) performance status, treatment duration, and relative dose intensity.
  • Adverse events, overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were assessed.

Main Results:

  • The 6-month progression-free survival (PFS) rate was 71.4%, and the overall survival (OS) rate was 100%.
  • The overall response rate (ORR) was 57.1%, with a disease control rate (DCR) of 71.4%.
  • The most frequent Grade 3 toxicities included AST elevation and hypertension (14.3% each).

Conclusions:

  • Lenvatinib demonstrated significant efficacy in advanced HCC patients, evidenced by high response and survival rates.
  • The observed toxicity profile was manageable, suggesting lenvatinib's potential as a standard treatment for advanced HCC.

More Related Videos

Laparoscopic Anatomical Resection of the Right Anterior Lobe Based on the Laennec Capsule Technique06:11

Laparoscopic Anatomical Resection of the Right Anterior Lobe Based on the Laennec Capsule Technique

Published on: May 2, 2025

441
Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience09:51

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience

Published on: December 4, 2023

1.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K